A chemical discovered at the University of California (UC) Davis may be a new, innovative tool to control depression, a severe and chronic psychiatric disease that affects 350 million people worldwide.
The research, led by UC Davis Superfund Research Program (SRP) Center Director Bruce Hammock, Ph.D., involves studies of an inhibitor of soluble epoxide hydrolase in rodents. Soluble epoxide hydrolase, or sEH, is emerging as a therapeutic target in humans that acts on a number of inflammatory or inflammation-linked diseases.
"The research in animal models of depression suggests that sEH plays a key role in modulating inflammation, which is involved in depression," said Hammock. "Inhibitors of sEH protect natural lipids in the brain that reduce inflammation and neuropathic pain. Thus, these inhibitors could be potential therapeutic drugs for depression."
The study, published in the journal Proceedings of the National Academy of Sciences, examined the role of the potent sEH inhibitor known as TPPU. The researchers found that TPPU displayed rapid antidepressant effects in rodents. They also found that expression of sEH was higher in key brain regions of chronically stressed mice than in control mice. For more information on the study and its authors, see the UC Davis press release.